Acyclovir
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Acyclovir
Description :
Acyclovir (Aciclovir) is a potent, orally active antiviral agent. Acyclovir has antiherpetic activity with IC50 values of 0.85 μM and 0.86 μM for HSV-1 and HSV-2, respectively. Acyclovir induces cell cycle perturbation and apoptosis. Acyclovir prevents bacterial infections during induction therapy for acute leukaemia[1][2][3][4].Product Name Alternative :
Aciclovir; AcycloguanosineUNSPSC :
12352005Hazard Statement :
H302, H315, H319, H335Target :
Antibiotic; Apoptosis; Bacterial; HSVType :
Reference compoundRelated Pathways :
Anti-infection; ApoptosisApplications :
COVID-19-anti-virusField of Research :
Cancer; InfectionAssay Protocol :
https://www.medchemexpress.com/Acyclovir.htmlConcentration :
10mMPurity :
99.34Solubility :
DMSO : ≥ 50 mg/mLSmiles :
O=C1NC(N)=NC2=C1N=CN2COCCOMolecular Formula :
C8H11N5O3Molecular Weight :
225.21Precautions :
H302, H315, H319, H335References & Citations :
[1]Benedetti S, et, al. Acyclovir induces cell cycle perturbation and apoptosis in Jurkat leukemia cells, and enhances chemotherapeutic drug cytotoxicity. Life Sci. 2018 Dec 15;215:80-85.|[2]Suzuki M, et, al. Synergistic antiviral activity of acyclovir and vidarabine against herpes simplex virus types 1 and 2 and varicella-zoster virus. Antiviral Res. 2006 Nov;72 (2) :157-61.|[3]Li Z, et, al. Acyclovir treatment of skin lesions results in immune deviation in mice infected cutaneously with herpes simplex virus. Antivir Chem Chemother. 1999 Sep;10 (5) :251-7.|[4]Lönnqvist B, et, al. Oral acyclovir as prophylaxis for bacterial infections during induction therapy for acute leukaemia in adults. The Leukemia Group of Middle Sweden. Support Care Cancer. 1993 May;1 (3) :139-44.Shipping Conditions :
Room TemperatureStorage Conditions :
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category :
Reference compound1Clinical Information :
LaunchedIsoform :
HSV-1; HSV-2CAS Number :
[59277-89-3]

